PubRank

John DiPersio

Author PubWeight™ 23.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006 8.57
2 Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009 1.42
3 Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2007 1.35
4 Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011 1.29
5 High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003 1.25
6 A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008 1.16
7 Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 2011 1.10
8 Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2009 1.10
9 AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 2007 1.08
10 Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005 1.06
11 Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003 0.85
12 Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic syndrome. Haematologica 2007 0.84
13 Cytokines and stem cell mobilization for autologous and allogeneic transplantation. Curr Hematol Rep 2004 0.82
14 T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant 2011 0.81
15 ASBMT committee report: white paper on measurement of quality outcomes. Biol Blood Marrow Transplant 2006 0.77
16 From trees to the forest: genes to genomics. Biol Blood Marrow Transplant 2011 0.76
17 Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine. Am J Hematol 2006 0.76
18 PCR for the diagnosis of toxoplasmosis after hematopoietic stem cell transplantation. Expert Rev Mol Diagn 2002 0.75